Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00403325 · ClinicalTrials.gov registry record · Phase 1
Intravitreal Ranibizumab Treatment of Central Serous Chorioretinopathy
A Phase 1 study of Central Serous Chorioretinopathy, sponsored by Vitreous -Retina- Macula Consultants of New York.
- Completed
- Registry status
- Phase 1
- Development phase
- 9
- Enrollment target
- 1
- Study location
NCT00403325: Completed Phase 1 study of Central Serous Chorioretinopathy, sponsored by Vitreous -Retina- Macula Consultants of New York.
NCT00403325 is a Phase 1 study of Central Serous Chorioretinopathy that has completed, run by Vitreous -Retina- Macula Consultants of New York. The registered enrollment target is 9 participants, below the 88-participant average among 5 other Central Serous Chorioretinopathy trials with a reported enrollment target (90% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00403325, a Phase 1 study of Central Serous Chorioretinopathy, has completed, sponsored by Vitreous -Retina- Macula Consultants of New York.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 9 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to examine the effects of Lucentis for active Central Serous Chorioretinopathy.
Conditions Studied
Interventions
- DRUG rhuFab V2 [ranibizumab] ( Lucentis )
Study Locations (1)
New York
- Vitreous Retina Macula Consultants of New York, P.C. - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2006-08 |
| Phase | Phase 1 |
What the finished NCT00403325 record still lists
NCT00403325 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 9 participants, a relatively small participant target, below the 88-participant average among 5 other Central Serous Chorioretinopathy trials with a reported enrollment target (90% lower).
The record links to 1 condition, with Central Serous Chorioretinopathy appearing as the primary indexed condition, and to 1 intervention - of which rhuFab V2 [ranibizumab] ( Lucentis ) is the first listed.
NCT00403325 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT00403325 about?
NCT00403325 is a clinical study titled "Intravitreal Ranibizumab Treatment of Central Serous Chorioretinopathy". The purpose of this study is to examine the effects of Lucentis for active Central Serous Chorioretinopathy.
What is the current status of trial NCT00403325?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 9 participants. The study started on 2006-08.
What conditions does trial NCT00403325 study?
This clinical trial studies the following conditions: Central Serous Chorioretinopathy.
What interventions are being tested in trial NCT00403325?
The interventions under investigation include: rhuFab V2 [ranibizumab] ( Lucentis ) (DRUG).
Who is sponsoring clinical trial NCT00403325?
This trial is sponsored by Vitreous -Retina- Macula Consultants of New York, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00403325 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Central Serous Chorioretinopathy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
OCT in Rare Chorioretinal Diseases
RECRUITING
-
Short-Term Oral Mifepristone for Central Serous Chorioretinopathy
COMPLETED · Phase 2
-
Genetic Analysis of Chronic Central Serous Chorioretinopathy Masquerading as Neovascular AMD
COMPLETED
-
Eplerenone for the Treatment of Central Serous Chorioretinopathy
COMPLETED · NA
-
The Safety & Efficacy of Intravitreal Aflibercept Injection in Patients With Persistent Central Serous Chorioretinopathy
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia